These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36348413)

  • 1. Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment.
    Olivier T; Prasad V
    BMC Med; 2022 Nov; 20(1):392. PubMed ID: 36348413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer.
    Olivier T; Haslam A; Prasad V
    BMC Med; 2023 Sep; 21(1):344. PubMed ID: 37679732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
    Sahin IH; Lin Y; Yothers G; Lucas PC; Deming D; George TJ; Kopetz S; Lieu CH; Dasari A
    Oncology (Williston Park); 2022 Oct; 36(10):604-608. PubMed ID: 36260786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
    Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
    Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa.
    Tan SX; Pumpalova Y; Rogers AM; Bhatt K; Herbst CL; Ruff P; Neugut AI; Hur C
    Cancer Med; 2023 Jul; 12(14):15515-15529. PubMed ID: 37318753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217).
    Folprecht G; Reinacher-Schick A; Weitz J; Lugnier C; Kraeft AL; Wisser S; Aust DE; Weiss L; von Bubnoff N; Kramer M; Thiede C; Tannapfel A
    Clin Colorectal Cancer; 2022 Jun; 21(2):170-174. PubMed ID: 34772609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
    Tsai M; Lo S; Audeh W; Qamar R; Budway R; Levine E; Whitworth P; Mavromatis B; Zon R; Oldham D; Untch S; Treece T; Blumencranz L; Soliman H
    JAMA Oncol; 2018 Jan; 4(1):e173470. PubMed ID: 29075751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study.
    Sue-Chue-Lam C; Brezden-Masley C; Sutradhar R; Yu AYX; Baxter NN
    Curr Oncol; 2023 Jul; 30(7):6508-6532. PubMed ID: 37504338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
    Slater S; Bryant A; Chen HC; Begum R; Rana I; Aresu M; Peckitt C; Zhitkov O; Lazaro-Alcausi R; Borja V; Powell R; Lowery D; Hubank M; Rich T; Anandappa G; Chau I; Starling N; Cunningham D
    BMC Cancer; 2023 Mar; 23(1):257. PubMed ID: 36941575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
    Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
    Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.
    Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Rodríguez-Salas N; Burgos E; Ramos D; Calatrava A; Andrada E; Díaz-López E; Sánchez A; Madero R; Cejas P; Feliu J
    Mol Cancer Ther; 2014 Sep; 13(9):2226-37. PubMed ID: 24980946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
    Benson AB; Schrag D; Somerfield MR; Cohen AM; Figueredo AT; Flynn PJ; Krzyzanowska MK; Maroun J; McAllister P; Van Cutsem E; Brouwers M; Charette M; Haller DG
    J Clin Oncol; 2004 Aug; 22(16):3408-19. PubMed ID: 15199089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives.
    Merk C; Martling A; Lindberg J; Benhaim L; Taieb J; Lind P
    Acta Oncol; 2022 Apr; 61(4):523-530. PubMed ID: 35139729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I treat stage II colon cancer patients.
    Taieb J; Karoui M; Basile D
    ESMO Open; 2021 Aug; 6(4):100184. PubMed ID: 34237612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.